Christopher Lipinski
Christopher Lipinski
Scientific Advisor Melior Discovery
Verified email at meliordiscovery.com - Homepage
TitleCited byYear
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
CA Lipinski, F Lombardo, BW Dominy, PJ Feeney
Advanced drug delivery reviews 64, 4-17, 2012
16490*2012
Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings
CA Lipinski, F Lombardo, BW Dominy, PJ Feeney
Advanced drug delivery reviews 23, 3-25, 1997
164581997
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
CA Lipinski, F Lombardo, BW Dominy, PJ Feeney
Adv. Drug Deliv. Rev 46 (1-3), 3, 2001
16420*2001
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
CA Lipinski, F Lombardo, BW Dominy, PJ Feeney
Advanced drug delivery reviews 46 (1-3), 3-26, 2001
16381*2001
Drug-like properties and the causes of poor solubility and poor permeability
CA Lipinski
Journal of pharmacological and toxicological methods 44 (1), 235-249, 2000
29872000
Lead-and drug-like compounds: the rule-of-five revolution
CA Lipinski
Drug Discovery Today: Technologies 1 (4), 337-341, 2004
18692004
Navigating chemical space for biology and medicine
C Lipinski, A Hopkins
Nature 432 (7019), 855-861, 2004
9012004
Poor aqueous solubility—an industry wide problem in drug discovery
C Lipinski
Am Pharm Rev 5 (3), 82-85, 2002
8672002
Chris Lipinski discusses life and chemistry after the Rule of Five.
CA Lipinski
Drug discovery today 8 (1), 12-16, 2003
1732003
Avoiding investment in doomed drugs
CA Lipinski
Curr Drug Discov 1, 17-19, 2001
1672001
Bioisosterism in Drug Design
CA Lipinski
Annual Reports in Medicinal Chemistry 21, 283-291, 1986
1631986
Quantitative Structure−Activity Relationships among Macrolide Antibacterial Agents:  In Vitro and in Vivo Potency against Pasteurella multocida
JW McFarland, CM Berger, SA Froshauer, SF Hayashi, SJ Hecker, ...
Journal of medicinal chemistry 40 (9), 1340-1346, 1997
1301997
Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions
CA Lipinski
Advanced drug delivery reviews 101, 34-41, 2016
1222016
A crowdsourcing evaluation of the NIH chemical probes
TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ...
Nature chemical biology 5 (7), 441-447, 2009
1092009
Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis
S Ekins, T Kaneko, CA Lipinski, J Bradford, K Dole, A Spektor, K Gregory, ...
Molecular bioSystems 6 (11), 2316-2324, 2010
662010
High throughput sonication: evaluation for compound solubilization
K Oldenburg, D Pooler, K Scudder, C Lipinski, M Kelly
Combinatorial chemistry & high throughput screening 8 (6), 499-512, 2005
632005
Synthesis and antitubercular activity of 7-(R)-and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy) benzyloxy)-6, 7-dihydro-5H-imidazo [2, 1-b][1, 3] oxazines, analogues of PA-824
X Li, UH Manjunatha, MB Goodwin, JE Knox, CA Lipinski, TH Keller, ...
Bioorganic & medicinal chemistry letters 18 (7), 2256-2262, 2008
602008
Medicinal chemistry of aldose reductase inhibitors
ER Larson, CA Lipinski, R Sarges
Medicinal research reviews 8 (2), 159-186, 1988
571988
Aldose Reductase Inhibitors as a New Approach to the Treatment of Diabetic Complications
CA Lipinski, NJ Hutson
Annual Reports in Medicinal Chemistry 19, 169-177, 1984
531984
Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists
CA Lipinski, JL LaMattina, PJ Oates
Journal of medicinal chemistry 29 (11), 2154-2163, 1986
521986
The system can't perform the operation now. Try again later.
Articles 1–20